Home › Trials › NCT04561518

Observational study of patients with ATTR amyloidosis

ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Observational Alnylam Pharmaceuticals · NCT04561518

This study looks at the characteristics of people with ATTR amyloidosis and tests how well existing treatments work for them in real life.

Quick facts

Study typeObservational
Enrollment1500 (estimated)
SexAll
SponsorAlnylam Pharmaceuticals Industry-sponsored
Locations40 sites (La Jolla, California and 39 other locations)
Trial IDNCT04561518 on ClinicalTrials.gov

What this trial studies

This study aims to describe the epidemiological and clinical characteristics of patients with transthyretin-mediated amyloidosis (ATTR amyloidosis). It will also evaluate the safety and effectiveness of existing treatments, patisiran and vutrisiran, in real-world clinical settings. Additionally, the study will monitor disease progression in individuals who are pre-symptomatic carriers of known disease-causing TTR variants. The research will be conducted in Germany and select sites in the United States.

Who should consider this trial

Good fit: Ideal candidates include individuals diagnosed with ATTR amyloidosis or pre-symptomatic carriers of known TTR variants.

Not a fit: Patients currently enrolled in clinical trials for investigational agents may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance understanding of ATTR amyloidosis and improve management strategies for patients.

How similar studies have performed: Other studies have shown success in characterizing ATTR amyloidosis, but this observational approach may provide novel insights into real-world management.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Diagnosis of ATTR amyloidosis or documented known disease-causing TTR variant for the cohort of pre-symptomatic carriers
* Germany Only: Patients must be treated per the summary of product characteristics (SmPC) for any approved treatment for ATTR amyloidosis

Exclusion Criteria:

* Current enrollment in a clinical trial for any investigational agent

Where this trial is running

La Jolla, California and 39 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Transthyretin-Mediated AmyloidosisATTR AmyloidosisRNAi therapeuticTransthyretinTTRAmyloidosisHereditary Transthyretin-mediated AmyloidosishATTR amyloidosis
Last reviewed 2026-06-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.